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Abstract
Measurement of N-terminal pro-B-type natriuretic peptide has been
shown a good rule-out test for cardiac dysfunction in patients in
the intensive care unit. The peptide measurement should not be
used as a replacement for other forms of monitoring, and performs
best as a diagnostic test when interpreted together with other
clinical findings and investigations. At a cutoff value similar to that
found in other clinical studies in acute decompensated heart
failure, measurement of N-terminal pro-B-type natriuretic peptide
offers an additional tool for diagnostic assessment of patients
presenting to the intensive care physician.
Measurement of the B-type natriuretic peptide (BNP) and
mesurement of the N-terminal portion of the prohormone, N-
terminal pro-B-type natriuretic peptide (NTproBNP), are part
of the routine assessment of patients presenting with acute
dyspnoea. The measurement of BNP/NTproBNP is now
included in the recommendations from professional societies.
Coquet and colleagues [1] have studied NTproBNP measure-
ment in the critical care population. They compared the
diagnostic performance of NTproBNP using a final diagnosis of
cardiac dysfunction based on a combination of clinical and
echocardiographic criteria. Using this diagnosis as the dichoto-
mous variable, the authors performed receiver operating
characteristic curve analysis and showed that the area under
the receiver operating characteristic curve was 0.76 (95%
confidence interval, 0.69 to 0.83) for the ability of NTproBNP
concentrations to detect cardiac dysfunction. In addition, using
a composite model including NTproBNP, electrocardiographic
changes and severity assessed by the organ system failure
score, the area under the receiver operating characteristic
curve for a final diagnosis of cardiac dysfunction improved to
0.83 (95% confidence interval, 0.77 to 0.90).
The Breathing Not Properly study, a multicentre evaluation of
BNP [2], the N-terminal pro-BNP Investigation of Dyspnoea in
the Emergency Department study [3] and the International
Collaborative NTproBNP study [4] for NTproBNP clearly
demonstrated that measurement of BNP is diagnostically
accurate when compared with a consensus final diagnosis of
acute heart failure and defined diagnostic cut-off values. The
study by Coquet and colleagues found that an NTproBNP
value <500 ng/l predicted the absence of cardiac dysfunction
with a sensitivity of 89% and a specificity of 43% [1]. Although
age and renal function affect NTproBNP levels, which is
reflected in reference ranges for this analyte, diagnostic
performance was not significantly affected. This value of
<500 ng/l is very similar to that proposed by other workers in
the field as a rule-out cutoff point for NTproBNP [4].
How should this translate into routine clinical practice? Are
NTproBNP measurements good surrogates for invasive
haemodynamic monitoring? NTproBNP measurements have
been compared with invasive haemodynamic measurements
in acute decompensated heart failure and found to show
good diagnostic performance [5] and a tight correlation
existed between BNP measurement and pulmonary capillary
wedge pressure as a dichotomous variable. Other studies
have shown in the intensive care unit that correlation between
natriuretic peptide measurements and invasively measured
haemodynamic parameters in the acute situation are relatively
poor [6-8]. When cardiac intensive care patients are used, a
more closely defined relationship is seen [9,10]. Measure-
ment of BNP or NTproBNP should not be used as a
substitute for other monitoring techniques in the intensive
care population.
The authors highlight that NTproBNP measurement is most
powerful when used as a rule-out test for cardiac dysfunction.
They also clearly demonstrate that the diagnostic power is
improved when interpreted with other variables. To misquote
John Donne, no test is an island. Elevation of NTproBNP
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occurs in a range of other clinical conditions other than
cardiac dysfunction, including sepsis [11]. Values are
frequently raised in the intensive care population, and both
BNP and NTproBNP measurements have been shown to be
prognostic in this population [12,13]. BNP and NTproBNP
values predict a poor prognosis when markedly elevated –
the death hormone.
The routine measurement of NTproBNP is certainly extremely
valuable as part of the initial assessment of a patient admitted
to intensive care as a rule-out test for cardiac dysfunction.
This measurement is not a rule-in test, and it is debatable
whether NTproBNP measurement should form part of routine
monitoring of the patient once they have been admitted.
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